OF
MDGL icon

Optimize Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

Optimize Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-992
Closed -$578K – 394
2025
Q4 		$578K Buy
992
+12
+1% +$6.13K 0.29% 92
2025
Q3 		$449K Buy
+980
New +$366K 0.23% 157

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Optimize Financial's MDGL Position: Q1 2026 in Review

Optimize Financial sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 992 shares — an estimated $578K sold.

Optimize Financial first reported a position in MDGL in Q3 2025 and held it in 2 quarters. The position peaked at $578K in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Optimize Financial reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Optimize Financial sold 992 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $578K.
  • Optimize Financial first reported a position in Madrigal Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Optimize Financial's Madrigal Pharmaceuticals position peaked at $578K in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Optimize Financial's 13F filing for Q1 2026, filed 12 May 2026.